Alzheimer's Disease and Anesthesia by Papon, Marie-Amélie et al.
www.frontiersin.org  January 2011  | Volume 4  | Article 272  |  1
Review ARticle
published: 31 January 2011
doi: 10.3389/fnins.2010.00272
Alzheimer’s disease and anesthesia
Marie-Amélie Papon1, Robert A. Whittington2, Noura B. El-Khoury1 and Emmanuel Planel1*
1  Département de Psychiatrie et Neurosciences, Centre Hospitalier de l’Université Laval, Québec, QC, Canada
2  Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Cognitive disorders such as postoperative cognitive dysfunction, confusion, and delirium, are 
common following anesthesia in the elderly, with symptoms persisting for months or years in 
some patients. Alzheimer’s disease (AD) patients appear to be particularly at risk of cognitive 
deterioration following anesthesia, and some studies suggest that exposure to anesthetics may 
increase the risk of AD. Here, we review the literature linking anesthesia to AD, with a focus on 
the biochemical consequences of anesthetic exposure on AD pathogenic pathways.
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symptoms may even persist for months or years in some patients 
(Bedford, 1955; O’Keeffe and Ni Chonchubhair, 1994; Moller et al., 
1998; Ancelin et al., 2001; Ahlgren et al., 2003; Seymour and Severn, 
2009; Fodale et al., 2010). Increasing age has been consistently iden-
tified as a risk factor for POCD (Moller, 1998; Moller et al., 1998; 
Monk et al., 2008). In a recent study, 25% of patients older than 
65 years developed delirium following surgery (Morimoto et al., 
2009); moreover, various studies have demonstrated short-term 
and  long-term  POCD  following  cardiac  and  non-cardiac  sur-
gery (Moller et al., 1998; Newman et al., 2001; Monk et al., 2008; 
Yoshitani and Ohnishi, 2009). Despite advances in perioperative 
care, POCD remains a major concern in AD patients as well as the 
elderly surgical population in general, as this condition has been 
associated with poor functional recovery, prolonged length of hos-
pital stay, increased hospital costs, decreased patient quality of life, 
and increased mortality (Francis et al., 1990; Marcantonio et al., 
1994; Bergmann et al., 2005; Xie and Tanzi, 2006). Interestingly, it 
has been suggested that the pathological mechanism(s) underlying 
POCD mimic AD (Xie and Tanzi, 2006; Fodale et al., 2010).
Indeed, anesthesia might be a risk factor for the development of 
neurodegenerative disorders such as AD and Parkinson’s disease. 
Patients with AD are considered to be particularly at risk for some 
of the cognitive side effects of anesthesia (e.g., delirium, POCD; 
Rees and Gaines III, 1985; Bone and Rosen, 2000; Fernandez et al., 
2003; Xie and Tanzi, 2006); however, there is also now concern that 
general anesthesia is a risk factor for AD with in vitro and in vivo 
studies suggesting that anesthetics may promote and intensify the 
neuropathogenesis of AD (Eckenhoff et al., 2004; Planel et al., 2007; 
Xie et al., 2007; Fodale et al., 2010). Several investigators have thus 
examined whether general anesthesia is associated with AD. Some 
studies find no association (Breteler et al., 1991; Bohnen et al., 
1994b; Gasparini et al., 2002; Zuo and Zuo, 2010), while interest-
ingly, others suggest that exposure to anesthetics may increase the 
risk of AD. For example, in a population 80 years of age or greater, 
general anesthesia was associated with a greater risk of developing 
INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent neurodegenerative 
disorder in elderly people; it afflicts an estimated 26.6 million peo-
ple worldwide, and without a major therapeutic breakthrough, the 
prevalence of AD is expected to increase to more than 100 million 
by 2050 (Brookmeyer et al., 2007). This disease is the most common 
form of dementia and the prevalence rates at ages 65, 75, and 85 years 
are 0.9, 4.2, and 14.7%, respectively (Brookmeyer et al., 2007).
The two histopathological hallmarks of AD are senile plaques 
composed of extracellular aggregates of the beta-amyloid pep-
tide (Aβ; Selkoe, 2001) and intraneuronal neurofibrillary tangles 
(NFTs), composed of abnormally hyperphosphorylated tau pro-
tein assembled into paired helical filaments (PHFs; Grundke-Iqbal 
et al., 1986; Buee et al., 2000). Only a small proportion of AD is 
due to genetic variants, the large majority of cases (over 99%) are 
late onset and sporadic in origin (Blennow et al., 2006). The cause 
of sporadic AD is likely to be multifactorial, with external factors 
interacting with biological or genetic susceptibility to accelerate 
the manifestation of the disease. The main risk factor for AD is 
age, and persons over age 85 have a six-fold increase of getting the 
disease (Harman, 2002; Bufill et al., 2009).
Exposure to anesthesia might be such an external factor. In 2004, 
it was estimated that 234.2 million people worldwide have surgery 
each year, approximately one operation for every 25 people (Weiser 
et al., 2008) and, as overall life expectancy has increased, an increas-
ing number of elderly patients are undergoing anesthesia. In this 
article, we review the relationship between anesthesia and AD as 
well as the impact of anesthesia on the two pathological hallmarks 
of AD: Aβ accumulation and aberrant tau phosphorylation.
CLINICAL STUDIES
The  evidence  that  anesthesia  produces  a  persistent  decrement 
in human cognition in certain susceptible patients is reasonably 
strong. Postoperative cognitive dysfunction (POCD), confusion, 
and delirium are common after general anesthesia in the elderly, and Frontiers in Neuroscience  | Neurodegeneration    January 2011  | Volume 4  | Article 272  |  2
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and Fodale (2009) showed a similar effect with clinically relevant 
concentrations of isoflurane and desflurane. Therefore, it seems 
that volatile anesthetics can promote Aβ oligomerization.
ANESThESIA AND Aβ pRODUCTION
Certain anesthetics have been demonstrated to also increase Aβ 
production in cell culture (Xie et al., 2006; Zhang et al., 2008). Xie 
et al. (2006) have shown that a concentration of 2% isoflurane for 
6 h altered processing of APP and increased production of Aβ in H4 
human neuroglioma cells. Furthermore, H4-APP cells treated with 
a combination of 12% desflurane and hypoxia (18% O2) for 6 h 
also altered APP processing and increased Aβ production (Zhang 
et al., 2008). The isoflurane-mediated elevation and aggregation 
of Aβ then induces further caspase-3 activation and apoptosis (Xie 
et al., 2006). Moreover, isoflurane-induced apoptosis can, in turn, 
increase β and g-secretase levels, thus promoting the two sequential 
cleavages of the APP to Aβ (Tagawa et al., 1991), perpetuating a 
vicious cycle (Xie et al., 2007).
The impact of anesthetics on Aβ production has also been exam-
ined in vivo. Bianchi et al. (2008) have demonstrated in female 
Tg2576  transgenic  mice  (harboring  the  human  APP-Swedish 
mutation thus increasing Aβ levels) that more amyloid plaques 
were observed following the administration of volatile anesthetics 
in comparison with control animals. In this study, mice were exposed 
to halothane (0.8–1%) or isoflurane (0.9–1%) for 120 min per day 
for 5 days. These investigators observed that halothane enhanced 
plaque deposition in the Tg2576 mouse model whereas isoflurane 
did not. On the other hand, isoflurane caused a decrease in cogni-
tive performance in wild-type animals that was not observed with 
halothane. Another group has observed that repetitive isoflurane 
anesthesia (4% for 1 min and maintained with 2% for 20–30 min) in 
Tg2576 mice, twice a week for 3 months, led to increased   mortality, 
AD (OR: 3.22; 95% CI: 1.03–10.09; p < 0.05; Bufill et al., 2009). 
Bohnen et al. (1994a) have demonstrated an inverse correlation 
between the age of AD onset and cumulative exposure to general 
and spinal anesthesia before the age of 50.
To date, few clinical studies have evaluated AD biomarkers in 
the cerebrospinal fluid (CSF) before and after surgery and anesthe-
sia. In a study limited to patients with idiopathic normal pressure 
hydrocephalus, Agren-Wilsson et al. (2007) reported that CSF AD 
biomarkers such as total tau (T-tau) and tau phosphorylated at 
Thr181 (P-tau) were significantly elevated following shunt sur-
gery, but Aβ42 did not change. It is well known that the pattern of 
AD CSF biomarkers is characterized by an increase in T-tau and 
P-Tau, but a decrease in Aβ42 (Andreasen et al., 2001). However, 
whether the effects are due to surgery or anesthesia is not clear, as 
a general increase of CSF spinal proteins after shunt insertion has 
previously been reported (Poca et al., 2001); moreover, a standard-
ized anesthesia protocol was not utilized in these studies. Similarly, 
Palotas et al. (2010) have reported gradual cognitive decline, sig-
nificantly decreased levels of Aβ peptides, and markedly increased 
tau protein concentrations in the CSF of patients 6 months after 
coronary artery bypass surgery.
Overall, clinical evidence establishing a link between anesthetic 
exposure and the risk of AD is inconsistent, with contradictory 
findings between studies. This is probably due to the lack of pro-
spective, randomized controlled studies that are designed to control 
for critical variables such as the type of surgery, duration of the 
procedure, age at exposure, pre-existing co-morbid disease, anes-
thetic technique, and patient temperature, thus making it extremely 
difficult to directly compare the results of these published studies. In 
addition, it is presently difficult to dissociate the effects of anesthesia 
from those of surgery. However, studies demonstrating postopera-
tive cognitive impairment associated with changes in biomarkers 
similar to that seen in AD, suggest some unifying pathognomonic 
factors between the two disorders (Palotas et al., 2010).
pRECLINICAL STUDIES
ANESThESIA AND Aβ OLIgOmERIzATION
Amyloid-beta (Aβ) is a peptide of 39–43 amino acids generated 
in vivo by specific proteolytic cleavage of amyloid precursor pro-
tein (APP), a transmembrane glycoprotein. Aggregated Aβ is the 
main constituent of amyloid plaques found in the brain of AD 
patients. It appears that soluble oligomeric Aβ forms, rather than 
amyloid plaques, contribute to the cellular pathology of the disease 
and correlate with the severity of cognitive impairment in humans 
(Lue et al., 1999). Different studies have shown that anesthetics can 
promote the oligomerization of Aβ peptide, supporting a potential 
link between anesthesia and the acceleration of Aβ-related toxicity 
(Eckenhoff et al., 2004; Carnini et al., 2007; Figure 1).
Initially, Eckenhoff et al. (2004) demonstrated that inhaled anes-
thetics (halothane and isoflurane) enhance fibril formation and 
the cytotoxicity of Aβ. Subsequent studies have shown that these 
inhaled anesthetics favor the formation of intermediate Aβ oligom-
ers (1–40) and reduce soluble Aβ (1–40) monomer forms (Carnini 
et al., 2007). Mandal and Pettegrew (2008) have demonstrated by 
nuclear magnetic resonance (NMR) that halothane and isoflurane, 
used at high concentrations, interact with a specific region of the Aβ 
peptide leading to Aβ oligomerization. Another study by Mandal 
Figure 1 | Theoretical pathways by which anesthesia could affect AD 
pathogenesis. Volatile anesthetics could promote Aβ pathology and NFT 
formation, both leading to a decrease in synaptic plasticity and 
neurodegeneration. Interestingly, anesthesia could enhance tau 
phosphorylation, either directly, through kinases activation, or indirectly, 
through hypothermia-induced phosphatases inhibition.www.frontiersin.org  January 2011  | Volume 4  | Article 272  |  3
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(Thr231), MC6 (Thr235), pS262 (Ser262), PHF-1 (Ser396/Ser404), and 
pS422 (Ser422) epitopes (Planel et al., 2007). Some of these phos-
phoepitopes are associated with early pre-tangle formation (pS422) 
(Augustinack et al., 2002) as well as later in PHF and NFT forma-
tion (AT8, PHF-1; Bramblett et al., 1993; Goedert et al., 1993, 1994). 
Furthermore, some phosphorylation sites have been linked to specific 
aspects of tau pathology such as the sequestration of normal tau 
(e.g., Thr231/Ser235; Alonso et al., 1997; Alonso Adel et al., 2004), the 
inhibition of tau MT binding (e.g., Ser262; Sengupta et al., 1998), and 
the promotion of tau aggregation (e.g., Ser396, Ser422; Gong and Iqbal, 
2008). As the restoration of normothermia in the mice completely 
returned phosphorylation to normal levels, tau hyperphosphoryla-
tion following these anesthetics was not mediated by the anesthetics 
per se, but was the consequence of anesthesia-induced hypothermia 
(Planel et al., 2007). Tau phosphorylation is exquisitely sensitive to 
temperature, increasing by 80% per degree Celsius drop under 37°C 
in mice (Planel et al., 2007). We also demonstrated in JNLP3 mice, 
a mouse model of tauopathy expressing P301L mutant tau (Lewis 
et al., 2001), that exposure to 1.3% isoflurane for 4 h increased tau 
phosphorylation at the AT8, CP13(Ser202), pS262, MC6, and PHF-1 
epitopes (Planel et al., 2009). Recently, another study confirmed 
these results in rats and demonstrated that 1.5% isoflurane for 2 h 
resulted in tau hyperphosphorylation at the Thr205 and Ser396 epitopes 
in the hippocampus, and that this effect was also due to anesthesia-
induced hypothermia (Tan et al., 2010). Other investigators have also 
confirmed our results of increased tau phosphorylation following 
anesthesia with sodium pentobarbital (Run et al., 2009), ketamine, or 
urethane (Holscher et al., 2008). One hour of pentobarbital anesthesia 
was associated with a decrease in body temperature and induced tau 
phosphorylation at the Thr181, Thr205, Thr212, and Ser262/Ser356 epitopes 
to a much larger extent than did anesthesia for 5 min (which did not 
induce hypothermia; Run et al., 2009). Therefore, it appears that a 
short exposure to anesthesia induces a slight increase in tau phos-
phorylation in a hypothermia-independent mechanism contrary to 
longer periods of anesthesia. Ether anesthesia, which also produces 
hypothermia (Hemingway, 1948), has also been reported to induce 
tau hyperphosphorylation in mice at Ser202/Thr205 and Thr231/Ser235, 
although these investigators did not report the temperature of the 
animals (Ikeda et al., 2007). Hence, general anesthetics are powerful 
thermoregulatory depressants leading to tau hyperphosphorylation 
through hypothermia, suggesting that hypothermia might increase 
tau pathology (Whittington et al., 2010); however, some anesthetics 
might have a temperature-independent effect on tau phosphoryla-
tion as well (Run et al., 2010; Figure 1).
Mechanisms of tau phosphorylation during anesthesia
We have also demonstrated that anesthesia-induced hypothermia 
leads to hyperphosphorylation of tau in the mouse brain due to 
the inhibition of PP2A activity (Planel et al., 2004, 2007). Another 
recent study has confirmed this result in rats (Tan et al., 2010). 
Tau hyperphosphorylation during hypothermia is mainly due to 
the direct inhibition of PP2A, as no single kinase is responsible 
for the hyperphosphorylation of tau at multiple epitopes observed 
under these conditions. However, it is important to understand 
that this statement does not imply that kinases are not involved in 
tau phosphorylation during hypothermia. On the contrary, in vivo 
tau hyperphosphorylation can be induced by basal kinase activity, 
less responsiveness, increased apoptosis, and increased Aβ aggre-
gation, changes that were not present in control mice (Perucho 
et al., 2010). In contrast, we did not detect any anesthesia-induced 
changes in either endogenous APP or APP C-terminal fragment 
levels; moreover, neither Aβ 1–40 nor Aβ 1–42 levels were altered 
following anesthesia (Planel et al., 2007). However, we only studied 
non-transgenic (C57BL/6J) mice 1 h following the induction of 
chloral hydrate anesthesia (i.p. 500 mg/kg). Our data are consist-
ent with a report demonstrating that acute (6, 12, 24, and 96 h) or 
chronic (1, 2, 3, and 4 weeks) anesthesia with thiopental or propofol, 
injected intraperitoneally at therapeutic (5 and 4 mg/kg respectively) 
or toxic doses (20 mg/kg), does not change APP protein and mRNA 
concentrations in the rat brain (Palotas et al., 2005). However, in 
our study as well as the investigation by Palotas et al. (2005) injected 
anesthetics were used, which could have different effects than the 
inhaled anesthetics used in the studies by Bianchi et al. (2008) and 
Perucho et al. (2010). Therefore, it seems that injected anesthetics 
have no effect on APP metabolism in wild-type animals, in contrast 
to inhaled anesthetics in AD models. These results suggest that ani-
mals with pre-existing Aβ pathology appear to be more at risk for 
the deleterious effects of certain inhalational anesthetics.
ANESThESIA AND TAU
Tau is a microtubule-associated protein (MAP) that is abundant in 
the CNS and expressed mainly in axons. In the human brain, tau is 
encoded by a single gene (located on chromosome 17) of 16 exons, 
generating 6 isoforms of 352–441 amino acids. The amino-terminal 
region, which is characterized by the presence or absence of one 
or two aminio acid inserts, has been found to interact with the 
plasma membrane and is essential for determining axonal diameter 
(Chen et al., 1992). The carboxy-terminal region is characterized 
by the presence of 3 or 4 repeats that mediate the microtubule 
(MT) binding properties of tau and promote MT stabilization and 
polymerization (Himmler et al., 1989; Butner and Kirschner, 1991; 
Gustke et al., 1994). These functions are negatively regulated by 
phosphorylation at multiple sites in, and around, the MT binding 
domain (Buee et al., 2000; Avila et al., 2004). Tau phosphorylation 
is regulated by numerous kinases and phosphatases; furthermore, 
glycogen synthase kinase-3 beta (GSK-3β) and protein phosphatase 
2A (PP2A) are considered to be the major tau kinase and phos-
phatase, respectively, regulating tau hyperphosphorylation in vivo 
(Planel et al., 2002; Tian and Wang, 2002).
Intracellular aggregates of abnormally hyperphosphorylated 
tau are present in a group of neurodegenerative diseases called 
tauopathies that include AD (Buee et al., 2000). Tau hyperphos-
phorylation can induce its aggregation in vitro (Alonso et al., 2001a; 
Sato et al., 2002), and is thought to induce NFT formation in the 
brain of AD patients (Trojanowski and Lee, 1994). Tau pathology 
has been observed to closely reflect the progression of dementia 
and memory loss in AD (Wilcock and Esiri, 1982; Arriagada et al., 
1992; Guillozet et al., 2003; Bretteville and Planel, 2008).
 Anesthesia and tau phosphorylation
We previously observed in the brain of non-transgenic mice that 
short-term  (30–60  min)  anesthesia  induced  by  chloral  hydrate, 
sodium pentobarbital, or isoflurane resulted in a robust hyperphos-
phorylation of tau at the pS199 (Ser199), AT8 (Ser202/Thr205), TG3 Frontiers in Neuroscience  | Neurodegeneration    January 2011  | Volume 4  | Article 272  |  4
Papon et al.  Alzheimer’s disease and anesthesia
hyperphosphorylation is thought to induce the formation of 
insoluble aggregates in vivo (Trojanowski and Lee, 1994). JNPL3 
mice readily develop such aggregates in the brain stem and con-
stitute a good model to study whether hyperphosphorylation 
accelerates tau aggregation in vivo. After 4 h of 1.3% isoflurane 
without temperature control, there was no change in the level 
of sarkosyl-insoluble tau in male and female mice. Although 
insoluble tau levels did not increase significantly immediately 
following a single exposure to isoflurane, they were elevated a 
week later in female mice only. Male mice are known to develop 
pathology at a slower rate than females due to reduced overall 
tau levels. Interestingly, multiple exposures to isoflurane (4 h to 
1.3% isoflurane twice a week for 2 weeks without temperature 
control) were accompanied by elevated tau aggregation in the 
brain stem of the male mice 1 week after the last exposure (Planel 
et al., 2009). These results confirm that exposure to anesthesia-
induced hypothermia can enhance tau pathology in JNPL3 mice, 
and suggest that repeated exposure is necessary to increase the 
pathology in male mice, in which tau aggregates are slower to 
form relative to female mice.
We thus evaluated whether increases in aggregated tau follow-
ing anesthesia affects the degenerative phenotype in JNPL3 mice. 
Although we observed the accumulation of aggregated tau 1 week 
after a single exposure to isoflurane in female mice, we did not 
observe a worsening of the degenerative phenotype as evaluated by 
a battery of motor function tests (rope hanging, tail hanging, and 
righting reflex). A similar result was observed following repeated 
exposure to isoflurane. One explanation could be that the levels 
of aggregated tau that accumulated in neurons were not enough 
to induce motor deficits. Indeed, our results show that insoluble 
tau levels correlate with the degree of motor impairment in JNPL3 
mice, but that anesthesia-induced accumulation of aggregated tau 
did not reach the threshold necessary for motor impairment (Planel 
et al., 2009).
CONCLUSION
Overall,  epidemiological  evidence  establishing  a  link  between 
  anesthetic exposure and the risk of AD remains controversial, with 
some studies finding an increased risk after anesthesia-exposure, 
and others finding no risk. Moreover, there is currently no direct 
evidence that anesthesia has a negative influence on the clinical 
course and outcome of patients with AD. On the other hand, 
clinical studies examining AD biomarkers postoperatively, and 
preclinical studies exploring the impact of anesthetics on Aβ and 
tau, converge to indicate that anesthetics could affect AD patho-
genesis, either directly or indirectly.
The therapeutic objective of general anesthesia is to produce 
analgesia, amnesia, hypnosis, and muscle relaxation to facilitate 
surgery. As such, general anesthetics provide immense benefits that 
likely outweigh the possible deleterious outcomes discussed above. 
Nevertheless, these potential toxic effects should be identified and 
their mechanisms investigated in order to mitigate any detrimental 
effects of anesthetic exposure, by the use of the safest drugs and 
techniques in patients with or at risk for AD (Baranov et al., 2009). 
Therefore, further clinical studies in humans examining the influ-
ence of anesthesia (both direct and indirect) on the subsequent 
development and progression of AD are warranted.
simply by a shift in the phosphorylation equilibrium as a result of 
phosphatase inhibition (Planel et al., 2007). In other words, inhibit-
ing PP2A is the functional equivalent of activating all the tau kinases 
together because PP2A dephosphorylates all the known tau epitopes 
while each kinase is specific for only a set of given sites (Wang et al., 
2007). Indeed, even when GSK-3β is inhibited as a consequence to 
hypothermia, it is still participating to the phosphorylation of tau, 
as we previously demonstrated with lithium, a GSK-3β inhibitor, in 
mice rendered hypothermic by starvation (Planel et al., 2001). Thus, 
hyperphosphorylation during anesthesia-induced hypothermia is 
due to direct inhibition of PP2A activity, an important finding since 
PP2A is inhibited in AD and seems to be an important factor in the 
evolution of AD pathology (Gong et al., 1993, 1995; Vogelsberg-
Ragaglia et al., 2001). However, Run et al. (2009) have demon-
strated that anesthesia for short periods (pentobarbital for 5 min) 
induced tau hyperphosphorylation in a hypothermia-  independent 
mechanism. This mechanism is probably due to activation of stress-
activated protein kinases, since c-Jun N-terminal kinase (JNK) and 
mitogen-activated protein kinase (MAPK) were activated during 
this phase. Therefore, with certain anesthetics, it appears that two 
mechanisms may underlie the induction of tau hyperphosphoryla-
tion: one indirect, linked to hypothermia and due to PP2A inhibi-
tion, and the other one more direct, independent of hypothermia, 
and involving protein kinases activation.
Functional consequences of tau phosphorylation during anesthesia
In vitro studies have demonstrated that hyperphosphorylation of 
tau can induce MT disruption (Ebneth et al., 1999) as well as tau 
aggregation (Alonso et al., 2001b; Sato et al., 2002). However, in adult 
C57BL/6J mice, we have observed that tau hyperphosphorylation by 
anesthesia-induced hypothermia impaired tau’s ability to bind and 
polymerize MTs, but did not lead to MT detachment (Planel et al., 
2008). MT-bound tau was more resistant to hyperphosphorylation 
compared with free tau, and tau did not dissociate from MTs in 
wild-type mice. Surprisingly, hyperphosphorylation of tau in hTau 
transgenic mice expressing all six isoforms of human tau (Andorfer 
et al., 2003, 2005), led to the specific dissociation of tau from the MTs 
in old mice. However, neither normal nor hTau mice, displayed a 
breakdown of MTs. Of note, in these studies, the mice were examined 
after only a few hours of anesthesia-induced hypothermia, and it is 
indeed possible that more prolonged anesthesia-induced hypother-
mia, even to a mild degree, could lead to more pronounced effects on 
tau function and MT network integrity. We subsequently confirmed 
these results in JNPL3 mice, a transgenic mouse strain harboring the 
human tau P301L mutation (Lewis et al., 2001). Following exposure 
to 4 h of 1.3% isoflurane twice a week for 2 weeks, we observed, in 
JNPL3 mice, the detachment of tau from MT without overall col-
lapse of the MT network (Planel et al., 2009). One explanation for 
the lack of MT disassembly might be that the remaining tau bound 
to MTs is sufficient to stabilize the cytoskeletal structure. Indeed, 
tau is known to fulfill its MT-stabilizing function in very minute 
amounts (Levy et al., 2005).
Pathological consequences of tau phosphorylation during anesthesia
After detaching from MTs, tau can aggregate, and it has been 
suggested that aggregated tau is the toxic species that causes 
cognitive  decline  in  AD  (Bretteville  and  Planel,  2008).  Tau www.frontiersin.org  January 2011  | Volume 4  | Article 272  |  5
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